TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published Nov. 4 in Science Translational Medicine found that tau accumulated at more than twice the rate in people with early-onset Alzheimer’s as in those with late-onset disease. The findings may help explain differences in symptoms and progression, but the study did not test treatments or establish why tau changes faster in younger patients.
A study of patients with Alzheimer’s disease found that tau accumulated at more than twice the rate in people whose symptoms began before age 65 than in those with later-onset disease, and was more widely distributed across the brain, as researchers investigate how Alzheimer’s spreads through the brain. Published Nov. 4 in Science Translational Medicine, the research may help explain why early-onset Alzheimer’s can progress faster and present with difficulties beyond memory, though it did not test treatments or establish what causes the difference.
The researchers compared 390 people with early-onset Alzheimer’s from the Longitudinal Early-Onset Alzheimer’s Disease Study with 211 people with late-onset disease from the Alzheimer’s Disease Neuroimaging Initiative. The groups’ average ages were 59 and 78, respectively. All participants had mild cognitive impairment or mild dementia attributed to Alzheimer’s, and PET scans showed amyloid, a biomarker associated with the disease.
A subset of participants had repeat tau PET scans over an average follow-up of two to three years, allowing the team to track changes in tau. The study found more extensive tau deposits and faster accumulation in the early-onset group, adding to research into what may trigger Alzheimer’s disease. It is described as the largest study to examine tau in early-onset Alzheimer’s and compare it with late-onset disease. The work was supported by the National Institute on Aging.
Among early-onset participants, one in five had a non-memory-dominant presentation. More than 99% of late-onset participants with documented presentations had a memory-dominant form. The researchers excluded people with known disease-causing mutations from the study, so the findings do not explain the role of those mutations in early-onset disease; other developments include an FDA-cleared blood test to aid evaluation for Alzheimer’s.
Tau Differences May Shape Symptoms
The findings offer a possible biological explanation for some differences reported between younger and older patients. Early-onset Alzheimer’s is more likely to begin with problems involving language, visual and spatial abilities, or executive functioning, rather than memory alone. The study’s results link early onset with more rapid tau accumulation, but they do not prove that tau alone causes these distinct symptoms or a faster course of disease.
The results may also matter for research into treatment. The two drugs approved to slow Alzheimer’s progression target amyloid, according to the report, while the differences between the age-of-onset groups in this study were greater for tau than for amyloid. Senior author Gil Rabinovici said the findings raise the possibility that tau-targeting treatments could be particularly relevant for early-onset disease. That is a research implication, not evidence that such treatment works better in younger patients: this study did not evaluate drug response.
Products Worth Considering
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Tau
Alzheimer’s disease is associated with changes in both amyloid and tau, proteins measured in this study using PET imaging. Participants already had mild cognitive impairment or mild dementia attributed to Alzheimer’s and amyloid accumulation on scans. Repeat tau imaging in a subset made it possible to compare how tau changed over time, rather than relying only on a single scan.
Early-onset Alzheimer’s refers here to symptoms beginning before age 65; late-onset refers to symptoms beginning at 65 or older. People with early-onset disease make up about 5% of Alzheimer’s patients, according to the report. The paper, “Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease,” appeared in Science Translational Medicine on Nov. 4, 2026.
“We don’t fully understand why Alzheimer’s develops so early in some people.”
— Konstantinos Chiotis, first author and assistant professor at Karolinska Institutet
Causes and Treatment Effects Remain Unknown
The study shows an association between early age of onset and more rapid tau accumulation, but does not explain why the difference occurs. Chiotis said researchers do not yet understand why Alzheimer’s develops early in some people and suggested that genetic factors beyond known disease-causing mutations may be relevant. The study excluded participants with known mutations and did not determine whether other genes account for the observed pattern.
The results also cannot show whether patients with early-onset disease respond differently to approved amyloid-targeting drugs or to treatments directed at tau. The analysis tracked imaging and clinical measures; it was not a treatment trial. The report does not specify how representative the imaging subsets were of all participants or provide enough detail to assess how the findings might apply across different patient populations.
Genetics and Combination Trials
Researchers may use the results to investigate whether genetic factors help explain the faster tau changes in early-onset disease and to identify possible treatment targets. Rabinovici said younger patients may be candidates for clinical trials combining amyloid- and tau-targeting approaches. Whether those trials will show a benefit, and whether any benefit differs by age of onset, remains to be tested.
For now, the study adds evidence about how tau patterns differ between early- and late-onset Alzheimer’s, but does not change what is known about the effectiveness of available treatments. The next evidence needed will come from studies that test therapies and follow patient outcomes, not imaging differences alone.
Key Questions
What did the study find about tau in early-onset Alzheimer’s?
It found that tau accumulated at more than twice the rate in the early-onset group compared with the late-onset group, with more extensive deposits and wider spread in the brain.
How did the researchers define early-onset Alzheimer’s?
The study classified early-onset disease as symptoms beginning before age 65. Late-onset disease refers to symptoms beginning at age 65 or older.
Does the study show that tau causes faster disease progression?
No. The results link faster tau accumulation with early-onset Alzheimer’s and may help explain differences in progression, but they do not prove tau is the sole cause of faster decline or distinct symptoms.
Did the study test Alzheimer’s treatments?
No. It compared tau PET imaging and patient characteristics; it did not test drugs or determine whether younger patients respond differently to amyloid- or tau-targeting treatments.
Why might the findings matter for future research?
The authors say the results may guide research into genetic factors and tau-targeting therapies. Trials would be needed to determine whether combining amyloid- and tau-targeting treatments helps patients with early-onset disease.
Source: news-medical.net
